Synopsis
Chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma represent various subtypes of B-cell lymphoid neoplasms with essential differences in cell origin, disease progression, and response to therapy. B-cell receptor (BCR) signaling has recently emerged as a central oncogenic pathway in these models, promoting tumor growth and survival. Here, we describe a new BCR-related kinase inhibitor, IQS019, which interacts with and efficiently prevents the activating phosphorylation of three apical BCR kinases (Syk, Lyn and Btk) in these models. Inhibition of BCR signaling by IQS019 leads to reduced cell proliferation, blockade of cell chemotaxis, and increased caspase-dependent apoptosis. Additionaly, in two different xenotransplant mouse models, treatment with IQS019 results in a remarkable decrease in BCR kinase phosphorylation and mitotic index, reduced tumor burden and tumor cell infiltration into the spleen. Altogether, these results warrant further investigation and clinical development of this novel BCR kinase inhibitor in mature B lymphoid malignancies.
"synopsis" may belong to another edition of this title.
About the Author
Gaël Roué received his PhD degree in 2002 at the University of Caen, France. After a first postdoctoral experience in the Pasteur Institute of Paris, he is now leading a team working on the development of new epigenetic, oncogene-, and microenvironment-targeting drugs for aggressive B-cell lymphoma, at the IDIBAPS institute in Barcelona, Spain.
"About this title" may belong to another edition of this title.
Search results for Activity of the Novel BCR Kinase Inhibitor IQS019 in...
Seller Image
Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL
Published by
LAP LAMBERT Academic Publishing Mai 2017, 2017
ISBN 10: 3330090715
ISBN 13: 9783330090712
New
Taschenbuch
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma represent various subtypes of B-cell lymphoid neoplasms with essential differences in cell origin, disease progression, and response to therapy. B-cell receptor (BCR) signaling has recently emerged as a central oncogenic pathway in these models, promoting tumor growth and survival. Here, we describe a new BCR-related kinase inhibitor, IQS019, which interacts with and efficiently prevents the activating phosphorylation of three apical BCR kinases (Syk, Lyn and Btk) in these models. Inhibition of BCR signaling by IQS019 leads to reduced cell proliferation, blockade of cell chemotaxis, and increased caspase-dependent apoptosis. Additionaly, in two different xenotransplant mouse models, treatment with IQS019 results in a remarkable decrease in BCR kinase phosphorylation and mitotic index, reduced tumor burden and tumor cell infiltration into the spleen. Altogether, these results warrant further investigation and clinical development of this novel BCR kinase inhibitor in mature B lymphoid malignancies. 64 pp. Englisch. Seller Inventory # 9783330090712
Stock Image
Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL
Published by
LAP LAMBERT Academic Publishing, 2017
ISBN 10: 3330090715
ISBN 13: 9783330090712
New
Paperback
Seller: Revaluation Books, Exeter, United Kingdom
Seller rating 5 out of 5 stars
Paperback. Condition: Brand New. 64 pages. 8.66x5.91x0.15 inches. In Stock. Seller Inventory # 3330090715
Buy New
£ 53.04
£ 10 shipping
Ships from United Kingdom to U.S.A.
Ships from United Kingdom to U.S.A.
Quantity: 1 available
Seller Image
Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL
Published by
LAP LAMBERT Academic Publishing, 2017
ISBN 10: 3330090715
ISBN 13: 9783330090712
New
Softcover
Seller: moluna, Greven, Germany
Seller rating 5 out of 5 stars
Condition: New. Seller Inventory # 151237536
Buy New
£ 27.91
£ 42.45 shipping
Ships from Germany to U.S.A.
Ships from Germany to U.S.A.
Quantity: Over 20 available
Seller Image
Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL
Published by
LAP LAMBERT Academic Publishing Mai 2017, 2017
ISBN 10: 3330090715
ISBN 13: 9783330090712
New
Taschenbuch
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma represent various subtypes of B-cell lymphoid neoplasms with essential differences in cell origin, disease progression, and response to therapy. B-cell receptor (BCR) signaling has recently emerged as a central oncogenic pathway in these models, promoting tumor growth and survival. Here, we describe a new BCR-related kinase inhibitor, IQS019, which interacts with and efficiently prevents the activating phosphorylation of three apical BCR kinases (Syk, Lyn and Btk) in these models. Inhibition of BCR signaling by IQS019 leads to reduced cell proliferation, blockade of cell chemotaxis, and increased caspase-dependent apoptosis. Additionaly, in two different xenotransplant mouse models, treatment with IQS019 results in a remarkable decrease in BCR kinase phosphorylation and mitotic index, reduced tumor burden and tumor cell infiltration into the spleen. Altogether, these results warrant further investigation and clinical development of this novel BCR kinase inhibitor in mature B lymphoid malignancies.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 64 pp. Englisch. Seller Inventory # 9783330090712
Seller Image
Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL
Published by
LAP LAMBERT Academic Publishing, 2017
ISBN 10: 3330090715
ISBN 13: 9783330090712
New
Taschenbuch
Seller: AHA-BUCH GmbH, Einbeck, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma represent various subtypes of B-cell lymphoid neoplasms with essential differences in cell origin, disease progression, and response to therapy. B-cell receptor (BCR) signaling has recently emerged as a central oncogenic pathway in these models, promoting tumor growth and survival. Here, we describe a new BCR-related kinase inhibitor, IQS019, which interacts with and efficiently prevents the activating phosphorylation of three apical BCR kinases (Syk, Lyn and Btk) in these models. Inhibition of BCR signaling by IQS019 leads to reduced cell proliferation, blockade of cell chemotaxis, and increased caspase-dependent apoptosis. Additionaly, in two different xenotransplant mouse models, treatment with IQS019 results in a remarkable decrease in BCR kinase phosphorylation and mitotic index, reduced tumor burden and tumor cell infiltration into the spleen. Altogether, these results warrant further investigation and clinical development of this novel BCR kinase inhibitor in mature B lymphoid malignancies. Seller Inventory # 9783330090712
Seller Image
Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL
Published by
LAP LAMBERT Academic Publishing, 2017
ISBN 10: 3330090715
ISBN 13: 9783330090712
New
Taschenbuch
Seller: preigu, Osnabrück, Germany
Seller rating 5 out of 5 stars
Taschenbuch. Condition: Neu. Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL | Gael Roué (u. a.) | Taschenbuch | 64 S. | Englisch | 2017 | LAP LAMBERT Academic Publishing | EAN 9783330090712 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. Seller Inventory # 109197633